Non-Invasive Prenatal Testing Market | Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China)

The global NIPT market is expected to reach USD 2.88 Billion by 2021 from USD 1.35 Billion in 2016, at a CAGR of 16.4% during the forecast period.
The non-invasive prenatal testing market is witnessing significant growth across the globe owing to factors such as high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, launch of new and advanced products, improving reimbursement scenario for NIPT, and programs focusing on increasing the awareness of NIPT.
Prominent players in the NIPT market include GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).
Non-Invasive Prenatal Testing (NIPT) Market
Illumina, Inc. (U.S.) held a leadership position in the NIPT market, owing to its wide product portfolio including sequencing, genotyping, gene expression, and molecular diagnostics. The company led the market with its flagship sequencing platforms: MiniSeq Sequencing, HiSeq Series (HiSeq 2500 and HiSeq 3000/4000), MiSeq Series, NextSeq 500, and HiSeq X Five and HiSeq X Ten. It also provides reagents such as NeoPrep Library Prep System, TruSeq library preparation kits, and other sequencing reagents. The company has a strong global presence. Illumina focuses on strengthening its position by entering into numerous agreements and partnerships with other small players in the market as well as by continuously launching new products in the market.
Currently, North America dominates the market, followed by Europe. However, the market in Asia is expected to witness the highest growth due to the increasing healthcare infrastructure. In addition, increasing awareness programs, rising disposable income, and increasing interest of players to expand in these emerging economies will propel the growth of the market.
Companies are focusing on adopting organic and inorganic growth strategies such as partnerships, agreements, collaborations, product launches, product enhancements, acquisitions, and expansions. These strategies help market players to strengthen their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
Location: Dundee Rd, Illinois, USA

Comments

Post a Comment

Popular posts from this blog

Key Players in the Pyrogen Testing Market Focus on Partnerships, Agreements, & Collaborations, Acquisitions, New Product launches, and Expansions

Image
The report  " Pyrogen Testing Market  by Product (Instruments, Services, Kits and Reagents), Application (Pharmaceutical & Biotechnology, Medical Devices, Other), & by Test (In Vitro, LAL, Gel Clot, Turbidimetric, Chromogenic, Rabbit) - Global Forecasts to 2021 " ,  report provides a detailed overview of the major drivers, restraints, opportunities, current market trends, and strategies impacting the global pyrogen testing market along with the estimates and forecasts of the revenue and market share analysis. Speak to Analyst @  https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=255266155 The global pyrogen testing market is valued at $462.38 million in 2014 and is expected to grow at a CAGR of 12.23%, to reach $823.14 million by 2019. Pyrogen testing is used to determine the bacterial toxins in products intended for medical or veterinary use. Rapidly growing pharmaceutical and biotechnology industries are a major growth driver for this market. Further
Read more

Non Invasive Prenatal Testing Market| Market Trends by Instruments, Consumables, Method, Application and End User

The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period. The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016, at a CAGR of 16.4% from 2016 to 2021. The instruments segment is divided into ultrasound device, NGS systems, PCR instruments, microarrays, and other instruments. In 2016, the consumables segment accounted for the largest share of the market. The high growth in this segment is attributed to the repeated requirements of consumables as compared to instruments in NIPT. Based on application
Read more

Global Glycomics Market Players Pursue the Strategies of Product Launches, Agreements, Expansions, Acquisitions, and Collaborations

Image
The major players in this market include Agilent Technologies (U.S.), Bruker Corp. (U.S.), Danaher Corp. (U.S.), New England Biolabs (U.S.), Prozyme Inc. (U.S.), Shimadzu Corp. (Japan), Sigma-Aldrich Corp. (U.S.), Takara Bio (Japan), Thermo Fisher Scientific (U.S.), and Waters Corp. (U.S.). The glycomics market is dominated by a few major players, with the top five players accounting for a majority of the market share. The top four players for glycomics enzymes, kits, and reagents have a combined market share of about 75.2% and for glycomics instruments have a combined market share of about 76.0%. The global glycomics market is highly evolved, with multiple different product segments. An analysis of market developments between 2011 and 2014 revealed that new product launches was the most important growth strategy employed by market leaders in this period. This strategy was adopted by most players in this market, except New England Biolabs (U.S.) and Takara Bio, Inc. (Japan).
Read more